



Book nr	Presentation / publication	Title	Sessions / Topic	Presenter
POSTER PRESENTATION				
Epidemiology				
157	POSTER	Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV-associated Aggressive B-cell Non-Hodgkin Lymphomas	Epidemiology	P. Ramakrishnan Geethakumari
Biology				
158	POSTER	TESTICULAR LARGE B-CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B-CELL LYMPHOMA	Biology	A. Rivas-Delgado
159	POSTER	Subgrouping of Burkitt lymphoma variants by DNA methylation is driven by an EBV-associated epigenotype	Biology	S. Glaser
160	POSTER	A transposable element atlas of aggressive B-cell non-Hodgkin lymphomas defines novel classifications of Burkitt lymphoma independent of EBV status	Biology	B. Singh
161	POSTER	Characterization of the genetic and epigenetic landscape of B-cell neoplasms with IG::BCL3-translocation	Biology	C. Drewes

162	POSTER	Genomic characterization of lymphomas in patients with inborn errors of immunity	Biology	Q. Pan-Hammarström
163	POSTER	Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib	Biology	J. A. Woyach
164	POSTER	The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation and small nucleolar RNA processing to sustain the survival of DLBCL cells	Biology	G. Sartori
165	POSTER	Alpha-ketoglutarate Suppresses Tumor Growth of Diffuse Large B-cell Lymphoma by Inducing Ferroptosis	Biology	Y. Cai
166	POSTER	CTPS1 acts as a prognostic biomarker and therapeutic target in mantle cell lymphoma	Biology	J. Liang
167	POSTER	Lipid metabolism reprogramming roles in mantle cell lymphoma growth and survival	Biology	J. Liang
168	POSTER	Deciphering the role of MSI2 as a regulator of stem-like properties in mantle cell lymphoma	Biology	V. Amador
169	POSTER	Lymph node location and retention properties of DC-SIGN engagement with the Immunoglobulin Oligomannoses of Follicular Lymphoma	Biology	F. Forconi
170	POSTER	CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through increasing BNIP3 expression	Biology	J. Liang
171	POSTER	Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon-beta (IFN- β) Gene Expression in Classical Hodgkin Lymphoma (cHL)	Biology	I. Xagoraris
Microenvironment				
172	POSTER	Unraveling the mechanisms of c-MYC-mediated escape from antibody and T-cell based anti-tumor immune attack in B-cell malignancies	Microenvironment	V. de Jonge

173	POSTER	Deciphering the role of macrophages and T cells in primary central nervous system lymphoma: tumour aggressiveness and response to immunotherapies	Microenvironment	C. Pagès-Geli
174	POSTER	The Immunobiology of histologic transformation in follicular lymphoma: a multi-omic case-control study	Microenvironment	J. C. Villasboas
175	POSTER	Spatial transcriptomic profiling: The “Next Generation Diagnosis” distinguishing between EBV+ lymphoproliferations with Hodgkin-like features	Microenvironment	M. R. Pugh
176	POSTER	Combined single-cell and spatially-resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organization	Microenvironment	S. Dietrich
177	POSTER	Digital spatial profiling of the tumor microenvironment in Hodgkin-like adult T-cell leukemia/lymphoma	Microenvironment	M. Takeuchi
178	POSTER	Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant proliferative drive CLL patients	Microenvironment	Y. Sha
179	POSTER	Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometry.	Microenvironment	A. Niu
180	POSTER	Prognostic values of circulating TREM2+ and ARG1+ Mreg cells in adults with treatment-naïve diffuse large B-cell lymphoma	Microenvironment	H. Wang
181	POSTER	Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma and cutaneous T-cell lymphoma	Microenvironment	N. L. Roberts
182	POSTER	Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma	Microenvironment	A. C. Kwang

183	POSTER	T cell CD62L expression following nivolumab therapy is associated with response to rituximab-nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study	Microenvironment	A. Barraclough
184	POSTER	RHOA deficiency drives decreased CD19 expression and immune dysregulation in CAR-T resistant diffuse large B-cell lymphoma	Microenvironment	J. Schatz
185	POSTER	Shelter in place: Live CLL cells inside the bone marrow fibroblasts and its implication in drug resistance	Microenvironment	Y. L. Wang
186	POSTER	Degradation of CD47-SIRP α axis by pomalidomide potentiates CD20 antibody-dependent cellular phagocytosis against B-cell lymphoma	Microenvironment	K. Zhou
187	POSTER	Targeting monocytic-myeloid suppressor cells through CSF1R-blockade enhances CD19-CAR T-cell response in DLBCL	Microenvironment	P. Gödel
188	POSTER	SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T-cell activity against large B-cell lymphoma	Microenvironment	M. R Green
189	POSTER	Prognostic impact of HLA-I neoantigen-specific CD8 ⁺ T cells in limited-stage follicular lymphoma	Microenvironment	J. W. Tobin
190	POSTER	Metabolic reprogramming of exhausted intratumoral CD8 ⁺ T-cell underlies anti-tumor activity of SUMOylation inhibitors in Large B Cell Lymphoma	Microenvironment	A. A. Merchant
191	POSTER	Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse	Microenvironment	F. Swain
192	POSTER	Enhancing T-cell responses to GCB-like lymphomas with immune-checkpoint-blockade-based therapies	Microenvironment	R. Zappasodi

193	POSTER	Itk inhibitor induces Th1 skewing and host anti-tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patients	Microenviron ment	N. Ding
194	POSTER	Determinants of response to T-cell stimulation by CD27 antibody therapy in lymphoma: The RiVa trial	Microenviron ment	S. H. Lim
195	POSTER	Gut microbiome in DLBCL patients undergoing first-line R-CHOP regimen – The Oncopassport Study	Microenviron ment	V. Stefoni
195 bis	POSTER	Plasma Protein Profiling using Multiplex Extension Assay in DLBCL. A descriptive study exploring plasma protein pattern evolution in DLBCL treated with R-CHOP.	Microenviron ment	A. H. Abu Sabaa
196	POSTER	Microbiota diversity in patients with Diffuse Large B-Cell Lymphoma and Immune-Privileged Sites Lymphoma	Microenviron ment	V. Herman
197	POSTER	Tayloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B-cell NHL	Microenviron ment	F. Gava
198	POSTER	Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non-Hodgkin lymphoma	Microenviron ment	N. Gower
Translational studies, B-cell lymphomas				
199	POSTER	Identification of an activated /memory B-cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patients.	Translational B cell	C. Laurent
200	POSTER	A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial	Translational B cell	P. Mozas
201	POSTER	Genetic Alterations in Follicular Lymphoma Predict Response to Very Low Dose Radiotherapy	Translational B cell	N. A. Wijetunga

202	POSTER	Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphoma	Translational B cell	M. B. H. Enemark
203	POSTER	Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non-H.pylori Helicobacter using multiplex PCR: a retrospective analysis	Translational B cell	M. Raderer
204	POSTER	Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real-World Diffuse Large B-cell Lymphoma Population	Translational B cell	W. Alduaij
205	POSTER	Identification of biomarkers for predicting central nervous system involvement in patients with diffuse large B-cell lymphoma	Translational B cell	C. Pagès-Geli
206	POSTER	Predicting cell of origin from digitized images of hematoxylin and eosin-stained slides of diffuse large B-cell lymphomas using a cell-based deep-learning model	Translational B cell	C. Laurent
207	POSTER	MYC negatively impacts treatment outcomes in stage II, but not stage I diffuse large B-cell lymphoma	Translational B cell	V. de Jonge
208	POSTER	A sub-population of cells expressing MYC and BCL2 without BCL6 refines the definition of double expressor lymphoma (DEL)	Translational B cell	A. D. Jeyasekharan
209	POSTER	Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor	Translational B cell	Z. Shi
210	POSTER	Biological and clinical relevance of CD79 protein and gene expression in diffuse large B-cell lymphoma	Translational B cell	Y. Naoi
211	POSTER	Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis	Translational B cell	H. Wan

212	POSTER	Genomic Correlates of Radiosensitivity in Diffuse Large B Cell Lymphoma	Translational B cell	R. R. Sarkar
213	POSTER	Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia	Translational B cell	S. Mebwe Pachong
214	POSTER	Next Generation Sequencing in routine diagnostics of mature non-Hodgkin's lymphomas. A single-center real-life data study	Translational B cell	M. F Breinholt
215	POSTER	Machine Learning-Based Stem Cell-Like Phenotype Identification and Novel Risk Stratification in Diffuse Large B-Cell Lymphoma: Multi-Omics Data from Multicenter Studies	Translational B cell	L. Wang
216	POSTER	LONG-TERM FOLLOW-UP AND GENE EXPRESSION PROFILES ASSOCIATED WITH OUTCOME IN PATIENTS WITH RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS TREATED IN THE NORDIC P[R]EBEN TRIAL	Translational B cell	T. Relander*

Translational studies, PTCL and cHL

217	POSTER	Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO-LINF study	Translational T/CHL	B. Casadei
218	POSTER	Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0.	Translational T/CHL	M. Federico
219	POSTER	Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profiles	Translational T/CHL	E. W. Y. Chang
220	POSTER	Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma	Translational T/CHL	I. Pal
221	POSTER	Serum Triglyceride and Apolipoprotein A1 as Biomarkers for Extranodal Natural Killer/T cell Lymphoma (ENKTL): A Multicenter Study	Translational T/CHL	Q. Cai

222	POSTER	Soluble immune checkpoints HVEM and TIM-3 are prognostic biomarkers for outcome in classical Hodgkin lymphoma	Translational T/CHL	J. Ferdinandus
223	POSTER	A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD courses.	Translational T/CHL	S. Luminari
224	POSTER	Deregulated hsa-miR-23a-3p and hsa-mir-148a-3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesis	Translational T/CHL	M. Giefing
225	POSTER	STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune Response	Translational T/CHL	G. Rassidakis
226	POSTER	Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosis	Translational T/CHL	M. D. Andersen
Translational studies, liquid biopsy				
227	POSTER	Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma	Translational Liquid Biopsy	M. C. Piroso
228	POSTER	Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study	Translational Liquid Biopsy	C. Rossi
229	POSTER	PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNA.	Translational Liquid Biopsy	A. Jiménez-Ubieto

230	POSTER	Genetic characterization in tissue and cfDNA in marginal zone lymphomas	Translational Liquid Biopsy	R. Diez-Feijóo
231	POSTER	Serial circulating tumor DNA sequencing reveals clonal dynamics and can offer treatment guidance in relapsed/refractory diffuse large B-cell lymphoma	Translational Liquid Biopsy	J. M. Heger
232	POSTER	Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B-cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody	Translational Liquid Biopsy	D. Soong
233	POSTER	Circulating tumour DNA concentration and genetic classification improve risk stratification in newly diagnosed patients with Diffuse Large B-Cell Lymphoma	Translational Liquid Biopsy	J. Arzuaga-Mendez
234	POSTER	Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL)	Translational Liquid Biopsy	J. Westin
235	POSTER	Clinical implications of ctDNA in predicting the genetic subtype, CNS involvement and outcomes of newly diagnosed diffuse large B cell lymphoma	Translational Liquid Biopsy	J. Liang

236	POSTER	Molecular characterization of diffuse large-B cell lymphoma by liquid biopsy at diagnosis and during follow-up. OBO "Euroclonality-NGS group" & "Grupo Colaborativo Linfomas y SLP de Cyl"	Translational Liquid Biopsy	M. E. Sarasquete
237	POSTER	Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t-cell therapy in non-Hodgkin B cell lymphoma.	Translational Liquid Biopsy	M. Bastos
238	POSTER	LIQUID BIOPSY FOR EARLY, NON-INVASIVE DIAGNOSIS OF EBV-POSITIVE BURKITT LYMPHOMA IN RESOURCE LIMITED SETTINGS	Translational Liquid Biopsy	C. C. Chamba
239	POSTER	Clinical impact of Epstein–Barr virus DNA in aggressive NK-cell leukemia	Translational Liquid Biopsy	A. Fujimoto
240	POSTER	Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T-cell lymphoma	Translational Liquid Biopsy	J. Liang
241	POSTER	Cell-free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study	Translational Liquid Biopsy	F. LEMONNIER

Imaging

242	POSTER	The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trial	Imaging	L. Guerra
243	POSTER	Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)	Imaging	C. Rossi
244	POSTER	Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B-cell lymphoma (DLBCL)	Imaging	J. T. Shreve
245	POSTER	An automated quantification algorithm for evaluating total metabolic tumor volume in patients with FDG-avid lymphomas using a deep learning model	Imaging	S. Jemaa
246	POSTER	Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B-cell lymphoma (DLBCL)	Imaging	A. M. Bock
247	POSTER	Differences in baseline PET/CT lymphoma distribution patterns between DLBCL-NOS and high-risk DLBCL patients	Imaging	K. J. Croese
248	POSTER	Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials – A LYSA retrospective analysis	Imaging	S. Amorim
249	POSTER	Modification of Lugano Criteria by Pre-Infusion Tumor Kinetics Improves Early Survival Prediction for Lymphoma Patients Under Chimeric Antigen Receptor T-Cell Therapy	Imaging	W. G. Kunz
250	POSTER	Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs – Data from International Prospective T-Cell Project 2.0	Imaging	T. Skrypets
251	POSTER	Interim 3-Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL)	Imaging	E. A. Hawkes

Hodgkin lymphoma

252	POSTER	Baseline-PET derived metrics are the most relevant factors for risk stratification in early-stage nonbulky HL: preliminary results of the RAFTING trial.	HL	A. Gallamini
253	POSTER	PET-Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin Lymphoma	HL	A. Moskowitz
254	POSTER	Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early-stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35-027 Part C)	HL	J. S. Abramson
255	POSTER	Impact of PET-2 guided treatment de-escalation on time-to-recovery from cancer-related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study	HL	J. Ferdinandus
256	POSTER	Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage	HL	A. Santarsieri
257	POSTER	'ACOPP' chemotherapy for older and less fit patients with Hodgkin lymphoma – a multicentre, retrospective study	HL	M. R. Wilson
258	POSTER	Brentuximab vedotin (BV) + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): incidence and management of peripheral neuropathy (PN) in a multi-institution cohort	HL	J. Svoboda
259	POSTER	BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma	HL	M. Carella
260	POSTER	Efficacy of brentuximab consolidation by metabolic response in an international real-world cohort of classic Hodgkin lymphoma at high risk for progression after ASCT	HL	S. H. Desai
261	POSTER	Toxicities at one year follow-up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group	HL	J. Ferdinandus
262	POSTER	Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma – Polish Lymphoma Research Group Study	HL	E. Paszkiewicz-Kozik

263	POSTER	An open-label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti-PD-1 treatment	HL	D. Lavie
264	POSTER	Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents.	HL	S. H Desai
265	POSTER	Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors.	HL	C. Pellegrini
266	POSTER	Secondary cancer is the leading cause of death 15 years or more after diagnosis of early-stage Hodgkin lymphoma	HL	I. Lagerlöf
267	POSTER	Overall survival and causes of death in elderly patients with Hodgkin lymphoma – a Norwegian population-based case-control study	HL	K. Lia
Indolent lymphomas				
268	POSTER	Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma	Indolent lymphomas	X. Wang
269	POSTER	Real-world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER-Medicare population	Indolent lymphomas	D. Chihara
270	POSTER	Analysis of Real-World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 Patients	Indolent lymphomas	L. H Sehn
271	POSTER	Real-World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	Indolent lymphomas	T. Best
272	POSTER	The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL) – a SCHOLAR-5 analysis	Indolent lymphomas	J. G. Gribben

273	POSTER	Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trial	Indolent lymphomas	L. Guerra
274	POSTER	Treatment outcomes of Limited Stage Grade 3A Follicular Lymphoma	Indolent lymphomas	R. R. Sarkar
275	POSTER	Outcomes in primary gastrointestinal (GI) follicular lymphoma (FL): results from a multicenter analysis	Indolent lymphomas	F. St-Pierre
276	POSTER	Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma	Indolent lymphomas	C. Ujjani
277	POSTER	A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular Lymphoma	Indolent lymphomas	P. Strati
278	POSTER	Outpatient administration of mosunetuzumab in US community practice settings: perspectives and learnings from the Phase II MorningSun study	Indolent lymphomas	J. M. Burke
279	POSTER	The impact of CHOP versus bendamustine on bone mineral density in patients with follicular lymphoma enrolled in the GALLIUM study	Indolent lymphomas	P. Jensen
280	POSTER	Evaluation of the GELTAMO guidelines for surveillance in follicular lymphomas after first-line immunochemotherapy: a real-world prospective study.	Indolent lymphomas	A. Salar Silvestre
281	POSTER	REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real-world prospective cohort.	Indolent lymphomas	C. Bommier
282	POSTER	Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)	Indolent lymphomas	C. Thieblemont

283	POSTER	Orelabrutinib, a new-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma	Indolent lymphomas	J. Zhu
284	POSTER	Long-term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial	Indolent lymphomas	J. Trotman
285	POSTER	A single-center experience of low-dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue (BALT)	Indolent lymphomas	K.Tringale
286	POSTER	Clinicopathological characteristics of extranodal marginal zone B-cell lymphoma of the intestine: a single center analysis	Indolent lymphomas	M. Raderer
287	POSTER	Autologous and allogeneic stem-cell transplantation for transformed Waldenström macroglobulinemia	Indolent lymphomas	E. Toussaint
288	POSTER	Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)	Indolent lymphomas	N. L. Berinstein
289	POSTER	Single-agent rituximab as an effective salvage therapy in pre-treated hairy cell leukemia	Indolent lymphomas	A. Broccoli
290	POSTER	Intralesional rituximab in the treatment of primary cutaneous B-cell lymphomas: a single-center experience	Indolent lymphomas	E. Domingo Domènech
Extranodal lymphomas non MZL				
291	POSTER	Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphoma	Extranodal Non MZL	K. R. Tringale
292	POSTER	Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R-PCNSL: A Multicenter Phase II Study	Extranodal Non MZL	Y. S. Choi

293	POSTER	Induction (MATRix) Followed by Transplantation in Primary Central Nervous System Lymphoma. Experience of the GELTAMO (Grupo Español de Linfoma y Trasplante de Medula Ósea).	Extranodal Non MZL	P. Lopez-Pereira
294	POSTER	Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients	Extranodal Non MZL	B. S. Imber
295	POSTER	Bone Marrow Assessment may be Omitted in Newly Diagnosed Diffuse Large B-Cell Lymphomas with Primary CNS Involvement	Extranodal Non MZL	F. Martin-Moro
296	POSTER	Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma	Extranodal Non MZL	J. H. Yi
297	POSTER	Preliminary results of penpulimab combined with RMA (rituximab, methotrexate, and cytarabine) for newly diagnosed primary central nervous system lymphoma (PCNSL)	Extranodal Non MZL	H. Shen
298	POSTER	Radiotherapy as an effective bridge for chemo-refractory or progressive secondary CNS lymphoma	Extranodal Non MZL	G. Cederquist
299	POSTER	Geriatric assessment scores: Predictors of prognosis and premature end of treatment in the MARTA and MARiTA study population of elderly PCNSL patients > 65 years	Extranodal Non MZL	A. Orbàn
300	POSTER	Primary Mediastinal B-cell Lymphoma, a nationwide real-life retrospective study from Fondazione Italiana Linfomi (FIL).	Extranodal Non MZL	E. Iannitto
301	POSTER	REAL-LIFE EXPERIENCE WITH RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS	Extranodal Non MZL	T. Vassilakopoulos
302	POSTER	Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B-cell lymphoma (r/r PMBCL) compared to DLBCL-NOS: A GLA/DRST registry study.	Extranodal Non MZL	M. Schubert

303	POSTER	Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35)	Extranodal Non MZL	M. C. Pirosa
DLBCL				
304	POSTER	Comparison Between aaPI, LAB-PI, NCCN-IPI and GELTAMO-IPI to Predict Prognosis in Elderly Patients with Diffuse Large-B Cell Lymphoma who Undergo R-CHOP/R-miniCHOP	DLBCL	F. Martin-Moro
305	POSTER	Patient- versus clinician-reported symptoms in the POLARIX study	DLBCL	C. A. Thompson
306	POSTER	Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the Phase 3 POLARIX study	DLBCL	B. Hu
307	POSTER	A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B-cell Lymphomas with Synchronous Systemic and Central Nervous System Involvement	DLBCL	J. E. Haydu
308	POSTER	Pola-R-CHP vs. R-CHOEP in young patients with high-risk diffuse large B-cell lymphoma	DLBCL	G. Lenz
309	POSTER	Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients ≤65 years of age with high-risk DLBCL: Interim analysis of COALITION	DLBCL	A. Minson
310	POSTER	Zanbrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line treatment for non-GCB diffuse large B-cell lymphoma: An updated analysis of efficacy and tolerability	DLBCL	H. Zhu
311	POSTER	Ibrutinib + bortezomib + R-CHOP for higher-risk DLBCL: Feasibility, efficacy and molecular predictors	DLBCL	S. Denker
312	POSTER	Pixantrone containing R-CPOP as firstline treatment in elderly DLBCL patients with congestive heart failure or high risk of anthracycline induced cardiotoxicity	DLBCL	R. Marks
313	POSTER	Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL	DLBCL	E. Verner

314	POSTER	The treatment of Burkitt lymphoma with the Berlin-Frankfurt-Münster protocol with rituximab and autologous transplantation	DLBCL	A. Broccoli
315	POSTER	Quality of life and response shift effect of diffuse large B-cell lymphoma French patients included in prospective real-life REALYSA cohort in the first year after diagnosis	DLBCL	H. Ghesquieres
316	POSTER	Trends in relative survival of Diffuse large B-cell lymphoma in Sweden in the era of targeted and cellular therapies	DLBCL	K. Ekström Smedby
317	POSTER	Defining Primary Refractory Diffuse Large B-cell Lymphoma (DLBCL) Based on Survival Outcomes	DLBCL	A. M Bock
318	POSTER	Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX	DLBCL	C. Herbaux
319	POSTER	Comparison of Clinical Outcomes in Patients With Relapsed/Refractory Large B-cell Lymphoma Treated With Epcoritamab vs Chemoimmunotherapy	DLBCL	A. Ip
320	POSTER	Novel therapies for the treatment of relapsed-refractory aggressive B-cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group	DLBCL	M. Bastos-Oreiro
321	POSTER	Venetoclax combined with R-ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy	DLBCL	P. F. Caimi
322	POSTER	Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non-Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).	DLBCL	L. FORNECKER
323	POSTER	Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L-MIND study	DLBCL	J. Duell
324	POSTER	Five-year subgroup analysis of tafasitamab + lenalidomide from the Phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma	DLBCL	J. Duell

325	POSTER	Tafasitamab plus lenalidomide versus standard of care as second-line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L-MIND (IN 2L-MIND)	DLBCL	L. H. Sehn
326	POSTER	Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non-Hodgkin lymphoma	DLBCL	Y. Koh
327	POSTER	Interim report from a phase 2 multicenter study of anti-PD-1 antibody (penpulimab) plus lenalidomide, rituximab, gemcitabine and oxaliplatin in Relapsed/ Refractory DLBCL	DLBCL	J. Liang
328	POSTER	Predictors of long-term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma	DLBCL	D. J Landsburg
329	POSTER	Autologous hematopoietic cell transplantation (autoHCT) for T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL): An EBMT Lymphoma Working Party study	DLBCL	S. Renders
330	POSTER	Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor-modified T cells	DLBCL	D. J Landsburg
331	POSTER	Prognostic factors for cellular therapies - CART and allogeneic SCT - in relapsed /refractory large B cell lymphoma (LBCL)	DLBCL	B. Glass
332	POSTER	Comparison of overall survival of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) adjusting for crossover in second-line (2L) R/R large B-cell lymphoma	DLBCL	F. Morschhauser
333	POSTER	CAR T treatment access and outcomes in patients with large B-cell lymphoma according to ethnicity and socioeconomic deprivation	DLBCL	D. Dragoi
334	POSTER	Efficacy of Subcutaneous Epcoritamab vs Axi-cel in R/R DLBCL CAR T-Naive and CAR T-eligible patients: An Indirect Comparison	DLBCL	A. Wang

335	POSTER	Efficacy and toxicity of CAR T-cell therapy in patients with primary and secondary central nervous system lymphoma – an analysis of the EBMT Lymphoma WP and the GoCART coalition	DLBCL	B. Glaß
336	POSTER	Treatment with anti CD19 CAR-T cells is safe and effective in patients with relapsed refractory large B-cell lymphoma with active central nervous system involvement	DLBCL	E. Robin Marieton
337	POSTER	Efficacy and safety of Axicabtagene ciloleucel (Axi-cel) for the treatment of relapse/refractory non-Hodgkin lymphoma: First real-world data in Chinese population	DLBCL	W. L. Zhao
CLL				
338	POSTER	Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single-arm study	CLL	M. Yi
339	POSTER	Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database	CLL	A. Tedeschi
340	POSTER	Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials	CLL	A. Tedeschi
341	POSTER	Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health-related quality of life	CLL	B. Eichhorst
342	POSTER	Ibrutinib (Ibr) for treatment of relapsed-refractory (R/R) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison of 3 randomized phase 3 trials	CLL	P. Ghia
343	POSTER	Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome	CLL	M. S. Davids
344	POSTER	Safety of acalabrutinib treatment in very old (≥ 80 y) and/or frail patients with chronic lymphocytic leukemia - interim safety analysis of the ongoing phase II CLL-Frail trial	CLL	F. Simon

345	POSTER	A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL	CLL	M. Shadman
MCL				
346	POSTER	Timing of disease progression and impact on survival in Swedish mantle cell lymphoma patients – a novel illness-death model study	MCL	S. Ekberg
347	POSTER	Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)	MCL	Y. Wang
348	POSTER	Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study	MCL	C. Visco
349	POSTER	Secondary malignancies in mantle cell lymphoma patients – A nationwide population-based study in Sweden	MCL	K. Abalo
350	POSTER	How to choose between curative radiotherapy or chemotherapy in low stage MCL? – a population-based analysis of outcome in patients with stage I-II MCL in Sweden	MCL	A. Albertsson-Lindblad
351	POSTER	Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG-MCL7-VALERIA)	MCL	L. Meriranta
352	POSTER	Long term follow-up of untreated/relapsing MCL patients with the ibrutinib, obinutuzumab, and venetoclax combination.	MCL	B. Tessoulin
353	POSTER	Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory B-cell malignancies	MCL	Y. Wang
354	POSTER	Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.	MCL	S. Carras

355	POSTER	Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial	MCL	D. Villa
356	POSTER	Venetoclax based combination therapy does not overcome poor outcomes in BTKi-refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax	MCL	D. S Wallace
357	POSTER	Analysis of immune and high-risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapy	MCL	A. Bottos
358	POSTER	Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatment	MCL	M. Shadman
359	POSTER	Outcomes of Bridging and Salvage Radiotherapy in Relapsed or Refractory Mantle Cell Lymphoma Patients Undergoing CD19-Targeted CAR T-Cell Therapy	MCL	C. Patel
PTCL				
360	POSTER	Long term outcome of Peripheral T Cell Lymphomas:10y follow-up analysis of the International Prospective T Cell Project Network	PTCL	M. Federico
361	POSTER	Diagnosis and management of adult T-cell leukemia/lymphoma in a Brazilian Cohort. T-cell Brazil Project.	PTCL	C. S Chiattonne
362	POSTER	Newly diagnosed extranodal natural killer/T cell lymphoma (ENKTL) treated by anti-PD-1 antibody plus histone deacetylase inhibitor followed by P-GemOx regimen	PTCL	H. Huang
363	POSTER	Enteropathy associated T-cell lymphoma: a population-based cohort study on incidence, treatment and outcome in The Netherlands	PTCL	F. O. Meeuwes
364	POSTER	Comparison of CHOP-like with or without Tucidinostat in the first-line treatment of Peripheral T-cell lymphoma:a retrospective propensity score-matched study	PTCL	X. Wen

365	POSTER	Role of upfront autologous stem cell transplantation (ASCT) in adults with T-NHL in first complete remission (CR1): A systematic literature review and meta-analysis	PTCL	P. L. Michelle
366	POSTER	A randomized phase II trial of CHOP vs ICED and autologous stem cell transplantation in newly diagnosed T-cell lymphoma	PTCL	K. H. Yoo
367	POSTER	Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology	PTCL	P. L. Zinzani
368	POSTER	Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study	PTCL	A. Fujimoto
369	POSTER	Efficacy of anti-PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA.	PTCL	A. Marouf
370	POSTER	Interim analysis of a prospective multicenter phase II study for advanced-stage or relapsed/refractory natural killer/T cell lymphoma	PTCL	W. Liu
371	POSTER	Pegarspargase and sintilimab for newly diagnosed, advanced stage natural killer T-cell lymphoma, nasal type: an open-label, single-arm, phase 2 study.	PTCL	J. Xiong
372	POSTER	Imatinib-induced complete and long-term sustained remission in chemotherapy-resistant systemic ALK-positive anaplastic large cell lymphoma	PTCL	A. Pichler
373	POSTER	Brigatinib in patients with ALK-positive anaplastic large cell lymphoma who have failed brentuximab vedotin	PTCL	D. Sibon
374	POSTER	Long-term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous t-cell lymphoma	PTCL	L. Bojanini

375	POSTER	Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of advanced extranodal NK/T-cell lymphoma	PTCL	L. Wang
376	POSTER	Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T-cell lymphoma: an interim analysis from a prospective, observational, real-world study	PTCL	M. Cai
377	POSTER	Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL	PTCL	S. S. Tolu
378	POSTER	Allogeneic transplantation in T-cell lymphoma: Lessons from the AATT study	PTCL	O. Tournilhac
Plasma cell neoplasms and amyloidosis				
379	POSTER	Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas	MM / Plasma cell / Amyloidosis	B. Fregonese
380	POSTER	Radiation in a new era of Multiple Myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response	MM / Plasma cell / Amyloidosis	A. D. Dreyfuss
CAR-T (Cellular therapies)				
381	POSTER	SAR444245, a non-alpha IL2, rescues chronic antigen and CAR-driven T-cell dysfunction	CAR-T (Cellular therapies)	M. R. Green

382	POSTER	Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells	CAR-T (Cellular therapies)	V. Vucinic
383	POSTER	Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor trafficking.	CAR-T (Cellular therapies)	V. Bachanova
384	POSTER	The Italian CART-SIE real life multicenter observational study on Chimeric Antigen Receptor T-cell (CAR-T) therapy for large B-cell (LBCL) and mantle cell (MCL) lymphomas	CAR-T (Cellular therapies)	A. Chiappella
385	POSTER	3-Year outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexu-cel in ZUMA-3 by age, prior therapies, and subsequent transplant	CAR-T (Cellular therapies)	M. Topp
386	POSTER	Matching-adjusted indirect comparison of axicabtagene ciloleucel vs mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments	CAR-T (Cellular therapies)	S. Kanters
387	POSTER	Outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe	CAR-T (Cellular therapies)	S. Choquet

388	POSTER	Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)	CAR-T (Cellular therapies)	S. Ahmed
389	POSTER	First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B-cell malignancies	CAR-T (Cellular therapies)	N. Kothari
390	POSTER	A Phase I Study of CD19-targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma	CAR-T (Cellular therapies)	M. L. Palomba
391	POSTER	Outcomes with bendamustine lymphodepletion and brexucabtagene autoleucel for mantle cell lymphoma	CAR-T (Cellular therapies)	E. A Chong
392	POSTER	Reasons for Discordance Among Imaging-based Response Criteria In Lymphoma Patients Receiving CAR T-cell Therapy	CAR-T (Cellular therapies)	M. Winkelmann
393	POSTER	CNS radiotherapy as bridging prior to CAR T-cell therapy for hematologic malignancies	CAR-T (Cellular therapies)	G. Cederquist

394	POSTER	Developing CAR-T-sparing Radiotherapy - early dosimetric results	CAR-T (Cellular therapies)	N. G. Mikhaeel
395	POSTER	Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma	CAR-T (Cellular therapies)	H. Hubbeling
396	POSTER	Predicting ICANS by means of plasma CAR-T cell derived extracellular vesicles in patients undergoing infusion of anti-CD19 CAR-T cells	CAR-T (Cellular therapies)	F. De Felice
397	POSTER	Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. A DESCAR-T study.	CAR-T (Cellular therapies)	S. Vic
398	POSTER	Neurotoxicity in patients with CNS lymphomas treated with CAR-T cell therapy. A LOC network study	CAR-T (Cellular therapies)	C. Houillier
399	POSTER	Factors Associated with Increased Risk of Major Cardiovascular Events for Patients Undergoing CAR T Therapy	CAR-T (Cellular therapies)	H. Reves

400	POSTER	Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004	CAR-T (Cellular therapies)	S. S. Kenderian
401	POSTER	'Don't keep me waiting': estimating the impact on lifetime survival and QALYs of reduced vein-to-vein time for LBCL patients treated with CAR T in the 3L+ setting	CAR-T (Cellular therapies)	R. Maziarz
402	POSTER	Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA program	CAR-T (Cellular therapies)	F. Colin
Preclinical new drugs				
403	POSTER	Drug-resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation	Preclinical New Drugs	S. Montoya
404	POSTER	BTM 3566, a Novel Activator of the Mitochondrial Stress Response Induces Robust Therapeutic Responses in Diffuse Large B-cell Lymphoma in vitro and in vivo.	Preclinical New Drugs	Z. Bashir
405	POSTER	MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemia	Preclinical New Drugs	W. Pappano
406	POSTER	Diffuse large B-cell lymphoma cell-cycle progression requires the cyclin-G associated kinase (GAK), a novel drug target from machine learning-enabled phenotypic screening	Preclinical New Drugs	O. B. Lightfuss
407	POSTER	BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models	Preclinical New Drugs	J. Rubenstein

408	POSTER	Differential ibrutinib sensitivity in Cd79b-mutant and wildtype subtypes of a novel Myd88-driven DLBCL mouse model	Preclinical New Drugs	G. Knittel
409	POSTER	Synthesis and Preclinical Development of a Promising Novel Romidepsin Nanoparticle for the Treatment of Peripheral T-Cell Lymphoma (PTCL)	Preclinical New Drugs	O. A. O'Connor
410	POSTER	Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos	Preclinical New Drugs	M. Zala
411	POSTER	CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents.	Preclinical New Drugs	M. J. Thomenius
412	POSTER	Orthotopic xenografts models in relapse/refractory lymphomas: a preclinical model for therapeutic, mechanistic and functional studies.	Preclinical New Drugs	E. Domingo Domenech
413	POSTER	Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti-Tumor Activity in a Preclinical Model of Non-Hodgkin's Lymphoma	Preclinical New Drugs	K. A. Logronio
414	POSTER	Prolonged cell cycle arrest by the CDK4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi-resistant mantle cell lymphoma	Preclinical New Drugs	N. Profitós-Pelejà
415	POSTER	MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 Inhibitors in ibrutinib resistance mantle cell lymphoma	Preclinical New Drugs	O. Hershkovitz- Rokah
416	POSTER	Interleukin-2-inducible kinase represents a novel therapeutic target for NK/T-cell lymphoma treatment	Preclinical New Drugs	J. Cao
417	POSTER	Brincidofovir induces potent anti-tumor activity in MYC-driven Natural Killer/T-cell Lymphoma with loss of transcriptional repressor TLE1	Preclinical New Drugs	J. Y. Chan

418	POSTER	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Janus kinase 1 (JAK1) inhibitor AZD4205 on Peripheral T cell lymphoma.	Preclinical New Drugs	Y. Ye
419	POSTER	AFM13 enhances the anti-tumor activity of AB-101 towards CD30+ tumors, conferring tumor growth control in vivo	Preclinical New Drugs	J. Pahl
Phase I-II				
420	POSTER	Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1	Phase I-II	M. Dreyling
421	POSTER	A phase II, open-label, multicenter study of capivasertib, a potent, oral pan-AKT inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CAPITAL)	Phase I-II	D. Hodson
422	POSTER	A phase 2 study of zilovetamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies: waveLINE-006	Phase I-II	P. L. Zinzani
423	POSTER	Updated follow-up of BELLWAVE-001: an open-label, single-arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B-cell malignancies	Phase I-II	H. Eradat
424	POSTER	Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors	Phase I-II	A. Olszewski
425	POSTER	Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T-cell Lymphoma (PTCL): Early trial analysis	Phase I-II	P. L. Zinzani
426	POSTER	Proof of concept of NX-2127, a first-in-class Bruton's Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with DLBCL	Phase I-II	A. Danilov
427	POSTER	Zilovetamab vedotin (MK-2140) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): 14-month follow-up of the phase 1 waveLINE-001 study	Phase I-II	M. L. Wang

428	POSTER	Robust Bruton's tyrosine kinase (BTK) degradation with NX-5948, an oral BTK degrader, in a first-in-human phase 1a trial in relapsed/refractory B cell malignancies	Phase I-II	K. Linton
429	POSTER	Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3K δ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma	Phase I-II	C. Carlo-Stella
430	POSTER	Liposomal doxorubicin supercharge-containing frontline treatment for diffuse large B-cell lymphoma or classical Hodgkin lymphoma: preliminary results of a phase II study	Phase I-II	C. Giordano
431	POSTER	Phase 2 KEYNOTE-B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL)	Phase I-II	W. Jurczak
432	POSTER	Response-adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis	Phase I-II	R. C Lynch
433	POSTER	Phase 2 study to investigate the efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study	Phase I-II	W. S. Kim
434	POSTER	First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients with B-Cell Lymphoma	Phase I-II	E. A Hawkes
435	POSTER	Phase 1 trial of E02463 peptide-based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non-Hodgkin lymphoma; EONHL1-20/SIDNEY	Phase I-II	A. A. Pinto
436	POSTER	Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check-point inhibitor (CPI).	Phase I-II	V. Bachanova
437	POSTER	Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL)	Phase I-II	C. J. Melani

438	POSTER	CC-99282 plus R-CHOP in patients (pts) with previously untreated aggressive B-cell lymphoma (a-BCL): early safety and efficacy results from a phase 1b study	Phase I-II	J. Munoz
439	POSTER	Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial	Phase I-II	T. Phillips
440	POSTER	Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)	Phase I-II	H. Lee
441	POSTER	CCTG LY18-A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma - the RGDP-Venetoclax substudy	Phase I-II	S. Assouline
442	POSTER	First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)	Phase I-II	H. Zhang
443	POSTER	Tafasitamab lenalidomide in relapsed/refractory large B-cell lymphomas: a multicentric real-world French experience study	Phase I-II	J. PAILLASSA
444	POSTER	Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma	Phase I-II	J. C. Villasboas
445	POSTER	Combination of everolimus and itacitinib in patients with Hodgkin lymphoma relapsed/refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPI)	Phase I-II	J. Svoboda
446	POSTER	Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non-Hodgkin lymphoma (R/R NHL): update of a Phase Ib study	Phase I-II	W. Townsend
447	POSTER	Combination of the PD-1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B-cell Lymphoma: Results from a Phase I/II Study	Phase I-II	D. A. Bond

448	POSTER	Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study:	Phase I-II	E. A Hawkes
449	POSTER	Risks and benefits of phase 1 clinical trials for patients with relapsed or refractory lymphoma, from 2008 to 2023.	Phase I-II	J. M. Michot
450	POSTER	Regulatory approvals and survival benefit for novel lymphoma drugs from 2013-2022	Phase I-II	E. R S. Cliff
451	POSTER	Association between Geriatric Impairments and Quality of Life in Older Adults with Lymphoma on Oral Targeted Therapies: A One-Year Prospective Study	Phase I-II	P. Torka

Pediatric / Young adults

452	POSTER	What drives pediatric Burkitt lymphoma? Timing events in the evolution of cancer using single-cell whole genome sequencing.	Pediatric / Young adults	A. Steemers
453	POSTER	Analyses of a patient with 3 sequential Post Transplant Lymphoproliferative Disease (PTLD) biopsies reveal persistence of Histone 1 gene mutation, suspected to mediate PTLD.	Pediatric / Young adults	B. Y. Ngan
454	POSTER	Abbreviated whole-body MRI for follow-up in pediatric lymphoma: results of a multicenter prospective study	Pediatric / Young adults	B. J. Zheng
455	POSTER	Characterization of clonal evolution in pediatric lymphoma using single-cell transcriptomics.	Pediatric / Young adults	R. D'aulerio

Infections

456	POSTER	Predicting COVID-19 infection risk in lymphoma by immune monitoring	Infections	S. H Lim
457	POSTER	Impact of COVID-19 infection on bispecific antibodies treatment in patients diagnosed with B-cell lymphoproliferative disorders	Infections	A. Serna
458	POSTER	Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report	Infections	J. Yang